SCHEMBL20876261

SCHEMBL20876261

C=C(c1ccccc1)c1cc(C(=O)OC)cc(C(=O)NC)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.47
RAB9A P51151 3/20 0.43
ACLY P53396 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
KDM4E B2RXH2 3/20 0.41
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
NFKB1 P19838 1/20 0.41
XDH P47989 1/20 0.41
GFER P55789 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
FUT7 Q11130 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HPGD P15428 2/20 0.41
MAPT P10636 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6539796 0.77 CA12 (0.56) TSHRRAB9AL3MBTL1KDM4ELMNA
SCHEMBL20876262 0.75 CYP1A2 (0.45) TSHRRAB9AACLYL3MBTL1KDM4E
SCHEMBL24592969 0.75 KDM4E (0.50) L3MBTL1KDM4ELMNAPOLBGAA
SCHEMBL20876266 0.74 KDM4E (0.49) ACLYL3MBTL1KDM4ELMNAPOLB
SCHEMBL20887339 0.74 ACLY (0.41) TSHRACLYL3MBTL1KDM4ELMNA
SCHEMBL20876254 0.73 TYR (0.47) TSHRRAB9AACLYL3MBTL1KDM4E
SCHEMBL13101770 0.73 TSHR (0.59) TSHRRAB9AKDM4ELMNAPOLB
SCHEMBL20876255 0.73 PPARA (0.43) TSHRRAB9AACLYL3MBTL1KDM4E
SCHEMBL9335427 0.71 TSHR (0.62) TSHRRAB9AL3MBTL1KDM4EPOLB
SCHEMBL12807357 0.71 KDM4E (0.57) TSHRL3MBTL1KDM4ELMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3692026-B1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-07-06 EP disclosed
EP-3692026-B1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-07-06 EP disclosed
US-11273146-B2 Benzofuran derivatives and their use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2022-03-15 US disclosed
US-11273146-B2 Benzofuran derivatives and their use as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2022-03-15 US disclosed
US-20200289464-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-09-17 US disclosed
US-20200289464-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-09-17 US disclosed
EP-3692026-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2020-08-12 EP disclosed
WO-2019068783-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289464-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRPF3 TSHR 3540/4885RAB9A 4417/4885ACLY 4133/4885
US-11273146-B2 Benzofuran derivatives and their use as bromodomain inhibitors BRD4, BRD3, BRPF3 TSHR 3540/4885RAB9A 4417/4885ACLY 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.